Skip to main content
Publications
Julvez J, Gignac F, Fernandez-Barres S, Romaguera D, Sala-Vila A, Ranzani OT, Persavento C, Delgado A, Carol A, Torrent J, Gonzalez J, Roso E, Barrera-Gomez J, Lopez-Vicente M, Garcia Esteban R, Boucher O, Forns J, Burgaleta M, Sebastian N, Canals J, Arija V, Basagana X, Ros E, Vendrell J, Salas-Salvado J, Sunyer J. Walnuts, long-chain polyunsaturated fatty acids, and adolescent brain development: protocol for the walnuts smart snack dietary intervention trial. Front Pediatr. 2021 Jun 8;9:593847. doi: 10.3389/fped.2021.593847
Mareque M, Montesinos P, Font P, Guinea JM, De La Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Saigi-Morgui N, Vandenberghe F, Delacretaz A, Quteineh L, Choong E, Gholamrezaee M, Magistretti P, Aubry JM, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Kutalik Z, Conus P, Eap CB. Association of PCK1 with body mass index and other metabolic features in patients with psychotropic treatments. J Clin Psychopharmacol. 2015 Oct;35(5):544-52. doi: 10.1097/JCP.0000000000000388